Development of a CRISPR/Cas-Based Detection Platform for Tracking Decreased Susceptibility to Cephalosporins in Neisseria gonorrheae حسب Ziyuan Zhao (2889005)

"…Developing efficient and accurate detection of resistant strains is urgently needed for their management and treatment. We have developed the Multiplex Integrated RPA-CRISPR/Cas12a detection Assay (MIRCA) for simultaneous detection of Neisseria gonorrheae (<i>Ng</i>) and mutations with decreased susceptibility to cephalosporins. …"

Descriptive statistics (means) for full sample and by lockdown status. حسب Drew B. Cameron (10687420)

الموضوعات:

Study sites and number of participants enrolled in the KAP and OOP surveys. حسب Drew B. Cameron (10687420)

الموضوعات:

Average cost per visit for HIV and HTN care (absolute vs. relative contributions). حسب Drew B. Cameron (10687420)

الموضوعات:

GLM models for predictors of monthly HTN care costs. حسب Drew B. Cameron (10687420)

الموضوعات:

Median monthly care costs, projected visits, and hospitalization costs. حسب Drew B. Cameron (10687420)

الموضوعات:

Average stability values (mean ± standard deviation) and statistical results. حسب Hyung Suk Yang (20442438)

الموضوعات:

Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Individual stability values for different gait events under various conditions. حسب Hyung Suk Yang (20442438)

الموضوعات:

Dynamic stability based on the Feasible Stability Region (FSR). حسب Hyung Suk Yang (20442438)

الموضوعات:

Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side. حسب Hyung Suk Yang (20442438)

الموضوعات:

Study Flowchart. حسب Jae-Heung Cho (798319)

الموضوعات:

Changes in outcomes over time. حسب Jae-Heung Cho (798319)

الموضوعات:

Study timetable. حسب Jae-Heung Cho (798319)

الموضوعات:

Cumulative incidence curves of recovery by group. حسب Jae-Heung Cho (798319)

الموضوعات:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

الموضوعات:

Participant demographic and clinical characteristics. حسب Claire M. Douglas (21238238)

الموضوعات:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... حسب Claire M. Douglas (21238238)

الموضوعات: